1. Home
  2. CNXC vs RAPP Comparison

CNXC vs RAPP Comparison

Compare CNXC & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Concentrix Corporation

CNXC

Concentrix Corporation

N/A

Current Price

$29.47

Market Cap

2.0B

Sector

Technology

ML Signal

N/A

Logo Rapport Therapeutics Inc.

RAPP

Rapport Therapeutics Inc.

N/A

Current Price

$23.21

Market Cap

1.4B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CNXC
RAPP
Founded
1991
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.4B
IPO Year
2020
2024

Fundamental Metrics

Financial Performance
Metric
CNXC
RAPP
Price
$29.47
$23.21
Analyst Decision
Buy
Strong Buy
Analyst Count
5
16
Target Price
$32.60
★ $64.21
AVG Volume (30 Days)
802.8K
★ 1.0M
Earning Date
09-29-2026
11-04-2026
Dividend Yield
★ 5.18%
N/A
EPS Growth
N/A
★ 24.34
EPS
N/A
★ N/A
Revenue
★ $9,825,771,000.00
N/A
Revenue This Year
$0.26
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 2.15
N/A
52 Week Low
$19.12
$22.06
52 Week High
$44.78
$52.93

Technical Indicators

Market Signals
Indicator
CNXC
RAPP
Relative Strength Index (RSI) 46.02 37.10
Support Level $28.51 $22.51
Resistance Level $30.75 $31.49
Average True Range (ATR) 1.90 1.45
MACD -0.41 0.16
Stochastic Oscillator 17.10 5.97

Price Performance

Historical Comparison
CNXC
RAPP

About CNXC Concentrix Corporation

Concentrix Corp is a technology and services company. It designs, implements, and manages end-to-end solutions, including customer experience process optimization, technology development and design engineering, front- and back-office automation, analytics, and business transformation services. The company serves clients across multiple industry verticals, helping them manage customer engagement and operational processes throughout the customer lifecycle. The company operates in a single operating segment. It generates revenue through the provision of technology and services under contractual arrangements. Geographically, the company generates the maximum revenue from the Philippines and the rest from India, the United States, Great Britain, Germany, Canada and Other countries.

About RAPP Rapport Therapeutics Inc.

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Share on Social Networks: